Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS3249109 A
Type de publicationOctroi
Date de publication3 mai 1966
Date de dépôt1 nov. 1963
Date de priorité1 nov. 1963
Numéro de publicationUS 3249109 A, US 3249109A, US-A-3249109, US3249109 A, US3249109A
InventeursMaeth Harry, Pennings Ralph David
Cessionnaire d'origineMaeth Harry, Pennings Ralph David
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Topical dressing
US 3249109 A
Images(1)
Previous page
Next page
Description  (Le texte OCR peut contenir des erreurs.)

Ma 3, 1966 H. MAETH ETAL 3,249,109

TORI CAL DRESS ING Filed Nov. 1, 1963 HARRY MA ETH R. DAVID PENNINGS BY Vndrus 9f Star/ 52 A'f-ronwsvs INVENTORS United States Patent 3,249,109 TOPICAL DRESSING Harry Maeth, 101 Main, and Ralph David Pennings, 302 Main, both of Mosinee, Wis. Filed Nov. 1, 1963, Ser. No. 320,809 9 Claims. (Cl. 128-268) This invention relates to a pharmaceutical preparation and more particularly to a pharmaceutical preparation for topical application to mucous membranes.

It is often desired to apply a dressing to the mucous membranes of the body, such as the oral cavity. For example, it may be desired to apply a post-operative dressing following gum surgery, or to use a dressing for intraoral traumatic wounds. In the past, dressings to be used in the oral cavity were generally made of tinfoil and included a base plate material which required heat to adapt it to its position on the membrane. If the dessing included a medicament or therapeutic agent, leakage of the agent generally occurred and could not be controlled. This resulted in the incomplete application of the agent to the site of treatment and dispersion of the agent into the mouth and possible entry into the alimentary tract.

The present invention is directed to an adhesive dressing to be topically applied to the body and in particular to the mucous membranes, such as the oral cavity. More specifically, the dressing or pharmaceutical preparation includes a flexible adhesive base composed of hydrated gelatin and including a small amount of pectin. In addition, a medicament or therapeutic agent can be incorporated in the flexible base. The base material is applied to the membrane at the site of the treatment and will adhere to the moist membrane. To prevent loss of the medicament or therapeutic agent, a backing member is applied to the outer surface of the flexible base. The backing member may take the form of a generally inert fabric, such as glass fibers, muslin or the like.

The hydrated gelatin base, which serves as the vehicle for the medicament or therapeutic agent, is flexible and is very adhesive and will readily adhere to the surfaces of the oral cavity or other mucous membranes. The gelatin base will remain flexible for extended periods of time and will not crack or chip. Moreover, the base does not contain oils or essential oils which can be irritating or toxic to the patient.

The use of the fabric backing layer insures theproper dosage of the medicament or therapeutic agent and prevents the dispersion of the agent from the site of treatment, thereby preventing the dispersion of the agent into the mouth and possible entry into the alimentary tract.

The pharmaceutical preparation or dressing can be used as a post-operative dressing in gum surgery, as a dressing for intraoral traumatic wounds, for the management of soft tissue lesions in the mouth, and as an irradiation shield for the treatment of malignant conditions with X-ray. In addition, it can also be used for topical application to the skin for abrasions, burns, varicose ulcers, and the like.

Other objects and advantages will appear in the course of the following description.

The drawings illustrate the best mode presently contemplated of carrying out the invention.

In the drawings:

FIG. 1 is a perspective view of a dressing prepared in accordance with the invention;

I FIG. 2 is a modified form of the invention showing the dressing in the form of a roll; and

FIG. 3 is a second modified form of the invention showing the dress-ing in the form of a pre-cut strip.

3,249,109 Patented May 3 1966 FIG. 1 shows a dressing 1 to be used for topical applications and particularly to the mucous membranes of the body. The dressing has particular application to the mucous membranes of the oral cavity, but also includes other areas such as the vagina, rectum, etc.

The dressing 1 includes a flexible hydrated gelatin base 2 and a fabric backing member 3. The hydrated gelatin base 2 contains by weight, 10 to 40% gelatin, 5 to Water, 15 to 80% polyhydric alcohol and up to 15% pectin.

The preferred range of composition, in weight percent is as follows:

Percent Gelatin 1033 Water 50-85 Polyhydric alcohol 15-35 Pectin 1-4 The hydrated gelatin gives the base its consistency and bulk and serves as the vehicle for the incorporation of medicaments and therapeutic agents.

Pectin is a carbohydrate obtained from the dilute acid extract of the inner portion of the rind of citrus fruits or apple peel. Pectin consists chiefly of partially methoxylated polygalacturonic acids.

The pectin provides adhesive properties to the hydrated gelatin and enables the gelatin base to be readily applied to moist surfaces, such as the mucous membranes.

The polyhydric alcohol serves to prevent brittleness and retains the flexible characteristics of the material for extended periods. The polyhdric alcohol can be glycerin, polyoxyethylene, propylene glycol, sorbitol, ethylene glycol (when used externally), and the like.

It is also contemplated that the base 2 will include a pharmacologically active material such as a medicament or a therapeutic agent. More specifically, the pharmacologically active material may include enzymes such as hyaluronidase; vasoconstrictors such as epinephrine; bactericides; bacteristatics; antacids; anesthetics; corticosteroids; antibiotics; hemostats; fluorides such as sodium fluoride, stannous fluoride, calcium fluoride; astringents, hormones; vitamins; tissue growth promoters such as Peruvian balsam; deodorants such as charcoal, and chlorophyll, and the like. The pharmacologically active material is used in an amount up to 10% by weight of the composition with the particular amount depending on the activity of the material.

The backing member 3 is formed of an inert, non toxic fibrous material such as glass fiber, muslin and the like. The use of glass fiber cloth has proven particularly satisfactory as a reinforcement and as a dam to reduce the spreading of the pharmacologically active material bility and a marked resistance to steam, corrosive fumes and most acids. In addition, the glass fiber will not absorb water and can be readily sterilized and re-sterilized and withstands repeated folding and creasing.

The fabric backing member 3 serves as a barrier and assures that the proper dosage of the medicament or therapeutic agent is supplied to the site to be treated. The backing member 3 prevents the agent from being dispersed into the mouth and prevents the entry of the agent into the alimentary tract.

To prepare the dressing of the invention, the gelatin and a portion of the Water and glycerin are mixed at an elevated temperature of about C. to form a gelatin component. ing portion of the water and glycerin to form a pectin component which is then added to the heated gelatin component. In some cases it may be desirable to add a The pectin is then mixed with the remainsmall amount, in the range of 1 to 2% of the total composition weight, of alcohol, such as ethyl alcohol, to the pectin component. The alcohol provides a rapid hydration of the pectin and can be omitted, but, if omitted, increases the time required for preparation.

After adding the pectin component to the gelatin component, the medicament or therapeutic agent is added as a solution or suspension, depending upon the particular agent used. The entire composition is then agitated to thoroughly mix the components and is subsequently poured into the desired mold and cooled. The backing member 3 is then overlayed onto the base material.

Example 1 As a specific example of the preparation, 30 grams of gelatin, 30 cc. of distilled water and 30 cc. of glycerin were mixed together and heated to a temperature of 90 C. to melt the gelatin. After the gelatin was melted, the pectin component consisting of 5 cc. of ethyl alcohol, 40 cc. of distilled water, cc. of glycerin and 5 grams of pectin was added to the liquid gelatin component and mixed therewith.

After adding the pectin component, 8 grams of Benzocaine and 40 cc. of alcohol, and 0.5 gram of Triburon (triclobisonium chloride) in 10 cc. of distilled water were added to the composition. After mixing in the Benzocaine and Triburon, the composition was poured into a mold and cooled. A glass fiber backing sheet was then overlayed over the composition and pressed firmly therein.

The resulting dressing was flexible and very adhesive and could readily be applied to mucous membranes.

Example 2 Three grams of pectin, 10 cc. of ethyl alcohol, 80 cc. of distilled water and 40 cc. of glycerin were mixed together. Forty grams of gelatin were added to this mixture and the entire composition heated to a temperature of 90 to 100 C. to melt the gelatin. Subsequently, 0.25

gram of Triburon in 17 cc. of glycerin and 20 cc. of distilled water were added to the gelatin-pectin composition. The resulting composition was then poured onto a suitable mold and cooled.

FIG. 2 shows a modified form of the invention in which the dressing is in strip form. In this embodiment the dressing includes a hydrated gelatin base 4 similar in composition to gelatin base 2 of the first embodiment. A fabric backing member 5 is applied to one surface of the base 4 and the backing member 5 is similar in structure and function to the backing member 3 of the first embodiment. In addition, a protective strip of material, such as waxed paper or other material, is applied to the outer surface of the barrier and serves to prevent the strip from sticking to itself when it is wound in spiral form.

The strip shown in FIG. 2 can be unwound as desired and cut to any length, depending on the nature of the site to be treated.

FIG. 3 shows a second modified form of the invention in which the dressing is in the form of a pre-cut strip. In this embodiment, the hydrated gelatin base 7, similar to base 2 of the first embodiment, is applied to an adhesive backing member 8. In this embodiment, a protective strip of material is applied to the adhesive surface of the strip 8 and can be removed immediately prior to application of the strip to the body surface.

The dressing of the invention is used for topical application, and particularly to the moist mucous membranes. For example, the dressing can be used as a post-operative dressing following surgery, as a dressing for traumatic wounds, 'as a dressing for soft tissue lesions and it also may be employed as an irradiation shield for the treatment of malignant conditions with X-ray. In this lattercase, a radiation barrier, such as powdered lead or barium sulphate, can be incorporated in the flexible base 2 in an amount of about 10 to 30% by weight of the base. The lead or barium sulphate is radiopaque material and serves as an irradiation shield to protect structures such as teeth and soft tissues from the radiation. This type of barrier is considerably more flexible and pliable than sheet lead for intraoral use, and being a lightweight material, is exceedingly more comfortable to the patient.

The dressing of the invention is flexible and will tightly adhere to moist membrane surfaces. If the dressing is to be applied to the external body tissues, it may be necessary to moisten the tissue before application.

It is contemplated that pharmacologically active materials can be incorporated in the hydrated gelatin base and the backing member serves to concentrate the activity of the material at the site of treatment and prevents the pharmacologically active material from dispersing outwardly into the mouth or other regions of the body.

Various modes of carrying out the invention are contemplated as being within the scope of the following claims particularly pointing out and distinctly claiming the subject matter which is regarded as the invention.

We claim:

1. A pressure sensitive dressing for topical application, comprising a solid, flexible hydrated gelatin base capable of maintaining its shape and containing a suflicient amount of pectin to provide initial adhesiveness for application to moist tissue and containing a sufiicient amount of a polyhydric alcohol to maintain flexibility for extended periods, and a generally inert non-toxic fibrous backing member disposed on one surface of said base and serving to prevent the outward dispersion of materials from the base.

2. A dressing for topical applications, comprising a solid, flexible, adhesive, film-like, hydrated gelatin base consisting essentially by weight of 10 to 40% gelatin, 5 to 85% water, 15 to of a polyhydric alcohol, and up to 15% pectin, and a fibrous backing member applied to one surface of the base, said backing member reinforcing the base and serving to prevent the outward dispersion of materials from the base.

3. The structure of claim 2, in which the hydrated gelatin base contains up to 10% by weight of a pharmacologically active material, said backing member serving to concentr-ate the pharmacologically active material at the site of treatment and preventing the outward dispersion of said material.

4. The structure of claim 2, in which the polyhydric alcohol is selected from the group consisting of glycerin, polyoxyethylene, propylene glycol, ethylene glycol, and sorbitol.

5. The structure of claim 3, in which the backing member is composed of glass fiber fabric.

6. A pressure sensitive dressing for topical applications, comprising a nonflow-able flexible, adhesive, hydrated gelatin sheet consisting essentially by weight of 10 to 33% gelatin, 50 to water, 1 to 4% pectin, 15 to 35% glycerin, and up to 10% of a pharmacologically active material, and a fabric backing member applied to one surface of the hydrated gelatin sheet, said backing member serving to concentrate the pharmacologically active material at the site of treatment and preventing the outward dispersion of said material.

7. The structure of claim 6 in which the hydrated gel-atin sheet also includes from 1 to 2% by weight of alcohol.

8. A dressing for topical applications, comprising a flexible, adhesive, hydrated gelatin base consisting essentially by weight of 10 to 40% gelatin, 5 to 85% Water, 15 to 80% of a polyhydric alcohol, up to 15% pectin and from 10 to 30% by weight of a material selected from the group consisting of lead and barium sulfate, and a fibrous backing member applied to one surface of the base, said backing member reinforcing the base and serving to prevent the outward dispersion of the material from the base, said material serving as a radiation shield to protect portions of the body from radiation.

9. A pressure sensitive article, comprising a flexible, adhesive, hydrated gelatin base containing up to 30% by weight of a radiopaque material, and a fabric backing member applied to one surface of the hydrated gelatin base, said backing member serving to concentrate the radiopaque material at the site of treatment and prevent the outward dispersion of said materiaL-said mtaerial serving as a radiation shield to protect portions of the article from radiation.

References Cited by the Examiner UNITED STATES PATENTS 307,537 11/1884 'Foulks 167 84 335,799 2/ 1886 Baby. 2,115,237 4/1938 Scholl 128268 X 6 Donaldson 1'28156 Shrontz 128-268 Reese.

Hirsch 106-125 Steinhardt 32--2 X FOREIGN PATENTS Germany.

OTHER REFERENCES Macleods Physiology in Modern Medicine, Bard, 8th edition, 1938.

ROBERT E. MORGAN, Primary Examiner.

15 RICHARD A. GAUDET, Examiner.

C. F. ROSENBAUM, Assistant Examiner.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US307537 *4 nov. 1884 Dental capsicum-bag
US335799 *26 oct. 18859 févr. 1886 Itnesses
US2115237 *11 mai 193626 avr. 1938Scholl William MMedicated button
US2450083 *7 févr. 194428 sept. 1948Munising Paper CompanyTreated paper liner for adhesive rolls
US2501544 *23 oct. 194621 mars 1950Shellmar Products CorpTherapeutic product
US2583341 *21 mars 195022 janv. 1952Reese John DSkin graft receiving member
US2950980 *10 sept. 195830 août 1960Arthur HirschAdhesive compositions
US3029187 *20 févr. 195810 avr. 1962Amos SteinhardtGelating adhesive pharmaceutical preparations
*DE1074979B Titre non disponible
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US3329145 *12 févr. 19654 juil. 1967Johnson & JohnsonSanitary napkin having control element with gel-forming material
US3339546 *13 déc. 19635 sept. 1967Squibb & Sons IncBandage for adhering to moist surfaces
US3444858 *11 mai 196620 mai 1969Higham S RussellMethod and means for administering drugs
US3598123 *1 avr. 196910 août 1971Alza CorpBandage for administering drugs
US3688406 *7 août 19705 sept. 1972Frank W HindsleyApparatus for and method of applying decay retardant compositions to teeth
US3696811 *17 juin 197110 oct. 1972Squibb & Sons IncPeriodontal bandage and backing therefor
US3769071 *4 juin 197130 oct. 1973Minnesota Mining & MfgPressure sensitive adhesive tape comprising 5-fluorouracil
US3960150 *15 sept. 19751 juin 1976Alza CorporationBioerodible ocular device
US3981303 *31 juil. 197521 sept. 1976Alza CorporationBioerodible ocular device
US3986510 *1 août 197519 oct. 1976Alza CorporationBioerodible ocular device
US3993071 *24 juil. 197523 nov. 1976Alza CorporationBioerodible ocular device
US3993073 *3 mars 197523 nov. 1976Alza CorporationNovel drug delivery device
US3996934 *9 août 197114 déc. 1976Alza CorporationMedical bandage
US3998215 *23 avr. 197121 déc. 1976Minnesota Mining And Manufacturing CompanyBio-medical electrode conductive gel pads
US4022203 *22 janv. 197610 mai 1977Win AckleyTreated patch for minor cuts
US4062361 *7 juil. 197513 déc. 1977Coloplast International A/SBilaminar ostomy sealing disc
US4239488 *15 juin 197916 déc. 1980Sempler Vance AEncapsulated denture adhesive and method of use
US4253460 *27 juil. 19793 mars 1981E. R. Squibb & Sons, Inc.Ostomy adhesive
US4265233 *6 avr. 19795 mai 1981Unitika Ltd.Material for wound healing
US4292299 *7 juil. 198029 sept. 1981Teijin LimitedSlow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4306551 *28 juil. 198022 déc. 1981Lectec CorporationSterile improved bandage and sealant
US4307717 *28 juil. 198029 déc. 1981Lectec CorporationSterile improved bandage containing a medicament
US4321252 *17 déc. 198023 mars 1982Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing ester derivatives of estradiol
US4329333 *24 nov. 198011 mai 1982Arthur BarrMethod for the oral treatment of dogs and other animals
US4460562 *30 mars 198317 juil. 1984Key Pharmaceuticals, Inc.Polymeric diffusion matrix containing propranolol
US4470962 *28 avr. 198111 sept. 1984Key Pharmaceuticals, Inc.Polyvinyl alcohol, polyvinylpyrrolidone, transdermal drugs
US4492685 *30 janv. 19848 janv. 1985Key Pharmaceuticals, Inc.Portection of burned or wounded patients
US4631227 *5 déc. 198323 déc. 1986Kenji NakamuraToilet article
US4655211 *8 août 19857 avr. 1987Unitika Ltd.Hemostatic agent
US4695465 *5 avr. 198522 sept. 1987Takeda Chemical Industry, Ltd.Soft patch
US4728323 *24 juil. 19861 mars 1988Minnesota Mining And Manufacturing CompanyAntimicrobial wound dressings
US4877618 *18 mars 198831 oct. 1989Reed Jr Fred DTransdermal drug delivery device
US4906475 *16 févr. 19886 mars 1990Paco Pharmaceutical ServicesEstradiol transdermal delivery system
US4984570 *14 sept. 198915 janv. 1991Karl Otto Braun KgHydrophilic absorbent cellulosic layer
US4991574 *15 août 199012 févr. 1991Dow Corning CorporationSurgical dressing
US5096715 *20 nov. 198917 mars 1992Alko Ltd.Containing a fixed dosage, a vehicle and permeation enhancer
US5207652 *23 oct. 19914 mai 1993BiodermMedical apparatus fixation and infection control device
US5234957 *23 déc. 199110 août 1993Noven Pharmaceuticals, Inc.Compositions and methods for topical administration of pharmaceutically active agents
US5332576 *21 mai 199326 juil. 1994Noven Pharmaceuticals, Inc.Local anesthetic, solvent, bioadhesive carrier
US5336501 *29 avr. 19929 août 1994Lohmann Gmbh & Co. KgCross-linked hydrogels and their use as wound dressings
US5437621 *12 janv. 19931 août 1995Marmon Holdings, Inc.Medical dressing of a multilayered material
US5446070 *27 août 199329 août 1995Nover Pharmaceuticals, Inc.Flexible, finite, bioadhesive, therapeutical agent in solid form
US5480377 *28 févr. 19942 janv. 1996New Dimensions In Medicine, Inc.Wound dressing having a roll configuration
US5536263 *30 mars 199416 juil. 1996Lectec CorporationNon-occulusive adhesive patch for applying medication to the skin
US5741510 *8 avr. 199621 avr. 1998Lectec CorporationTransdermal delivery
US5829442 *12 juin 19963 nov. 1998Medical Concepts Development, Inc.Antimicrobial containing solventless hot melt adhesive composition
US6016862 *10 mars 199925 janv. 2000Hormel Foods CorporationSand core
US6090915 *18 oct. 199618 juil. 2000Hormel Foods CorporationCollagen or gelatin crumble composition and uses
US6096333 *8 oct. 19971 août 2000Lectec CorporationMethod of forming adhesive patch for applying medication to the skin
US6096334 *14 déc. 19981 août 2000Lectec CorporationSelf-supporting flexible sheet; fluid adhesive
US646922712 mai 200022 oct. 2002Lectec CorporationAntipruritic patch
US660774624 juil. 200219 août 2003Medical Concepts Development, Inc.Antimicrobial containing solventless hot melt adhesive composition
US66643097 déc. 200016 déc. 2003Bostik Findley, Inc.Antimicrobial hot melt adhesive
US708726922 juin 20018 août 2006Lg Chemical Co., Ltd.Preparing a precursor film by injection of a polymer, which is used for a support layer, into an extruder; annealing the precursor film; coating with polymer solution; drying; low temperature-stretching; high temperature-stretching; heat-setting
US715761421 déc. 20012 janv. 2007Fountainhead, LlcLayer of polymeric gel block copolymer and mineral oil, and a second layer containing bactericidal silver metal in nylon fabric; dentistry, periodontal disease; appliances for mouth, nose, or other body cavity; bite blocks or plates, caps, braces
US735789130 janv. 200415 avr. 2008Monosol Rx, LlcProcess for making an ingestible film
US742529214 févr. 200216 sept. 2008Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US766633728 mai 200423 févr. 2010Monosol Rx, LlcPolyethylene oxide-based films and drug delivery systems made therefrom
US782458814 avr. 20082 nov. 2010Monosol Rx, LlcWater degradation; controlled drying; digestible film containing water soluble polymer
US791064114 déc. 200622 mars 2011Monosol Rx, LlcPH modulated films for delivery of actives
US797261820 sept. 20075 juil. 2011Monosol Rx, LlcEdible water-soluble film containing a foam reducing flavoring agent
US801715022 avr. 200813 sept. 2011Monosol Rx, LlcPolyether combined with hydrophilic cellulosic material; demonstrates non-self-aggregating, uniform heterogeneity; mucosally adhesive water soluble product containing analgesic opiate; preventing air pocket formation during production
US84758327 août 20092 juil. 2013Rb Pharmaceuticals LimitedSublingual and buccal film compositions
US860351410 juil. 200710 déc. 2013Monosol Rx, LlcUniform films for rapid dissolve dosage form incorporating taste-masking compositions
US861417917 juil. 200924 déc. 2013E-Therapeutics PlcAntibacterial combination therapy for the treatment of gram positive bacterial infections
US865237829 mars 201318 févr. 2014Monosol Rx LlcUniform films for rapid dissolve dosage form incorporating taste-masking compositions
US866368713 mai 20104 mars 2014Monosol Rx, LlcFilm compositions for delivery of actives
US868543726 mars 20091 avr. 2014Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US87651678 sept. 20061 juil. 2014Monosol Rx, LlcUniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
EP0044624A1 *23 juin 198127 janv. 1982E.R. Squibb & Sons, Inc.Lyophilized hydrocolloid foam
EP0159168A2 *4 avr. 198523 oct. 1985Takeda Chemical Industries, Ltd.Soft patch drug preparation
EP0161681A2 *15 mai 198521 nov. 1985Mitsubishi Acetate Co., Ltd.Gel plate and process for preparing same
EP0167263A1 *28 mai 19858 janv. 1986Matrix Pharmaceutical Inc.Drug-containing matrices for introduction into cellular lesion areas
EP0177920A2 *7 oct. 198516 avr. 1986Teijin LimitedPharmaceutical composition for external use containing active type vitam D3
EP0232580A2 *21 août 198619 août 1987Alza CorporationTransdermal system II
EP0297828A1 *28 juin 19884 janv. 1989The Kendall CompanyNovel medicated dressings
EP0438749A1 *20 déc. 199031 juil. 1991Beiersdorf AktiengesellschaftSelf-adhesive mass from gelatine
EP0666081A1 *20 janv. 19959 août 1995Bristol-Myers Squibb CompanyWound dressing
EP0852148A17 janv. 19978 juil. 1998Israel Fiber InstituteProducts having anti-microbial activity
EP2014282A220 juin 200814 janv. 2009E-Therapeutics plcTreatment of depression
EP2508231A215 nov. 200710 oct. 2012E-Therapeutics PlcImidazoles for treating multi-drug resistant bacterial infections
EP2529733A118 juil. 20085 déc. 2012E-Therapeutics PlcAntibacterial combination therapy
EP2529737A118 juil. 20085 déc. 2012E-Therapeutics plcAntibacterial combination therapy
WO1993007928A1 *23 oct. 199229 avr. 1993Bioderm IncMedical apparatus fixation and infection control device
WO2009013480A218 juil. 200829 janv. 2009E Therapeutics PlcAntibacterial combination therapy
WO2011030106A110 sept. 201017 mars 2011E-Therapeutics PlcCancer cell apoptosis
WO2012046006A27 oct. 201112 avr. 2012University Of DundeeCancer targets
WO2012104589A12 févr. 20129 août 2012University Of EdinburghWeight related disorders
WO2013160645A126 avr. 201331 oct. 2013E-Therapeutics PlcDexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg
WO2013164561A13 mai 20137 nov. 2013E-Therapeutics PlcTramadol for treating depression
Classifications
Classification aux États-Unis604/304, 602/49, 433/180, 602/50
Classification internationaleA61K9/00, A61F13/00, A61F13/15, A61L15/58, A61L15/44
Classification coopérativeA61F2013/00659, A61K9/006, A61L15/44, A61F2013/00472, A61F2013/53445, A61F13/122, A61L15/585, A61F13/0236, A61F13/8405, A61L2300/00, A61F13/00063
Classification européenneA61L15/58M, A61K9/00M18D, A61L15/44, A61F13/00